{"id":7078,"date":"2011-11-22T13:00:31","date_gmt":"2011-11-22T18:00:31","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=7078"},"modified":"2011-11-22T13:02:23","modified_gmt":"2011-11-22T18:02:23","slug":"medimmune-univ-of-michigan-to-partner-on-biologics","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=7078","title":{"rendered":"MedImmune, Univ. of Michigan to Partner on Biologics"},"content":{"rendered":"<p><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/10\/DrugVials_HeyPaul.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-full wp-image-1427\" title=\"DrugVials_HeyPaul\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/10\/DrugVials_HeyPaul.jpg\" alt=\"Drug vials (Hey Paul\/Flickr)\" width=\"212\" height=\"200\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/10\/DrugVials_HeyPaul.jpg 212w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/10\/DrugVials_HeyPaul-150x141.jpg 150w\" sizes=\"auto, (max-width: 212px) 100vw, 212px\" \/><\/a><a href=\"http:\/\/www.med.umich.edu\/\">University of Michigan Medical School<\/a> in Ann Arbor and <a href=\"http:\/\/www.medimmune.com\/Default.aspx\">MedImmune<\/a> in Gaithersburg, Maryland have agreed to collaborate on research leading to new biologic therapies for a range of diseases. MedImmune is the biologics division of the global pharmaceutical company AstraZeneca.<\/p>\n<p><a href=\"http:\/\/www.medimmune.com\/research_biologics.aspx\">Biologics<\/a> are treatments or therapies developed through biological processes, such as genes or cellular products, rather than synthesized from chemicals. Researchers from Michigan&#8217;s Medical School and MedImmune are expected to cooperate on studies that translate lab findings into candidates for treating cancer initially, but also heart, digestive system, lung, and inflammation-related diseases.<\/p>\n<p>The university says research conducted in this joint program, both pre-clinical and translational, will be designed to identify and confirm the specific molecules and genes involved in causing disease, and potential molecules and cell-based therapies to treat or prevent them. The scientists from the medical school and company plan to collaborate on projects, while preserving academic freedom, research integrity, and both parties&#8217; rights to intellectual property for discoveries.<\/p>\n<p><span style=\"color: #777777;\">Read more: <a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=3022\">AstraZeneca, HealthCore Partner on Health Outcomes Research<\/a><\/span><\/p>\n<p>Photo: <a href=\"http:\/\/www.flickr.com\/photos\/heypaul\/2101849662\/in\/photostream\/\">Hey Paul\/Flickr<\/a><\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>University of Michigan Medical School in Ann Arbor and MedImmune in Gaithersburg, Maryland have agreed to collaborate on research leading to new biologic therapies for a range of diseases. MedImmune is the biologics division of the global pharmaceutical company AstraZeneca. Biologics are treatments or therapies developed through biological processes, such as genes or cellular products, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[31,51,64,27,26],"class_list":["post-7078","post","type-post","status-publish","format-standard","hentry","category-ventures","tag-biomedical","tag-cancer","tag-life-sciences","tag-pharmaceuticals","tag-university"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/7078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7078"}],"version-history":[{"count":6,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/7078\/revisions"}],"predecessor-version":[{"id":7083,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/7078\/revisions\/7083"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}